8-K: Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds

Phio Pharmaceuticals has terminated its share purchase agreement with Triton Funds due to a drop in the company's stock price below the agreed purchase price.

Summary

• Phio Pharmaceuticals terminated a share purchase agreement with Triton Funds on July 3, 2024.
• The agreement, established on May 16, 2024, allowed Triton to purchase up to 95,833 shares of Phio's common stock for a total of $621,000.
• The purchase price was set at $6.48 per share, adjusted for a 1-for-9 reverse stock split effective July 5, 2024.
• Triton had the right to reduce the number of shares purchased if the stock price fell below $6.48.
• On July 3, 2024, Phio's stock price closed at $5.23 per share.
• Phio's Board of Directors decided to terminate the agreement and pursue alternative financing.
• No shares were sold to or purchased by Triton under the agreement.

Sentiment

Score: 4

Explanation: The termination of the share purchase agreement and the need to seek alternative financing is a negative development, indicating potential financial challenges. However, the company is proactively addressing the situation.

Positives

• Phio's management proactively terminated the agreement to seek better financing options.
• The company avoided selling shares at a price below the agreed upon value.

Negatives

• The termination of the agreement indicates a potential need for alternative financing.
• The stock price falling below the agreed purchase price suggests market concerns.

Risks

• Phio Pharmaceuticals needs to secure alternative financing after terminating the agreement with Triton Funds.
• The company's stock price volatility could impact future financing efforts.
• The termination of the agreement may raise concerns among investors about the company's financial stability.

Future Outlook

Phio Pharmaceuticals will be seeking alternative financing options after terminating the agreement with Triton Funds.

Management Comments

• The Board of Directors determined that it was advisable and in the best interests of the Company and its stockholders to terminate the Purchase Agreement and pursue alternative financing.

Industry Context

The termination of the agreement highlights the challenges faced by biotechnology companies in securing financing, especially when stock prices are volatile. This is not uncommon in the biotech sector where funding is often tied to market performance and clinical trial progress.

Comparison to Industry Standards

• Many small-cap biotech companies rely on equity financing to fund operations and research.
• The termination of a share purchase agreement due to stock price decline is not unusual in the biotech industry, where market sentiment can be highly sensitive to news and clinical trial results.
• Comparable companies often use similar financing methods, such as private placements or public offerings, and face similar risks related to stock price volatility.

Stakeholder Impact

• Shareholders may be concerned about the company's financial stability and the need for alternative financing.
• Employees may be indirectly affected by the company's financial situation.
• Customers and suppliers may not be directly impacted by this announcement.

Next Steps

• Phio Pharmaceuticals will seek alternative financing options.
• The company will continue to develop its INTASYL technology.

Key Dates

Keywords

share purchase agreement, financing, stock price, termination, Triton Funds, Phio Pharmaceuticals, common stock, reverse stock split